COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
Open Access
- 25 June 2024
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 96 (4) , 678-693
Abstract
Objective: To assess comparative effectiveness, safety, and tolerability of off‐label rituximab, compared with frequently used therapies approved for multiple sclerosis (MS).Methods: A Swedish cohort study of persons with relapsing–remitting MS, age 18 to 75 years at inclusion and with a first therapy start or a first therapy switch between 2011 and 2018. Low‐dose rituximab was compared with MS‐approved therapies. Primary outcomes were proportions with 12 months confirmed disability worsening and change in MS Impact Scale‐29 (MSIS‐29) scores, respectively. Secondary endpoints included relapses, therapy discontinuation, and serious adverse events. Analyses used an intention‐to‐treat approach and were adjusted for demographics, MS features, and health characteristics.Results: We included 2,449 participants as first therapy start and 2,463 as first therapy switch. Proportions with disability worsening at 3 years were 9.1% for rituximab as first therapy and 5.1% after therapy switch, with no differences to MS‐approved comparators. Worsening on rituximab was mostly independent of relapses. MSIS‐29 with rituximab at 3 years improved by 1.3/8.4 points (physical/psychological) for first disease‐modifying therapy (DMT) and 0.4/3.6 for DMT switch, and was mostly similar across therapies. Rituximab had lower relapse rates and higher therapy persistence in both groups. The rate of hospital‐treated infections was higher with rituximab after a therapy switch, but not as a first therapy.Interpretation: This population‐based real‐world cohort study found low rates of disability progression, mostly independent of relapses, and without significant differences between rituximab and MS‐approved comparators. Rituximab led to lower rates of inflammatory activity and higher treatment persistence, but was associated with an increased rate of serious infections. ANN NEUROL 2024;96:678–693Keywords
Funding Information
- Patient-Centered Outcomes Research Institute (MS‐1511‐33196)
This publication has 37 references indexed in Scilit:
- Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness StudyAnnals of Neurology, 2024
- Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older‐Onset Multiple SclerosisAnnals of Neurology, 2023
- Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System LevelAnnals of Neurology, 2022
- Diagnosis and Treatment of Multiple SclerosisJAMA, 2021
- Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsAnnals of Neurology, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJAMA, 2019
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple SclerosisJAMA Neurology, 2018
- B‐cell Therapy for Multiple Sclerosis: Entering an eraAnnals of Neurology, 2017
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006